These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16730719)

  • 1. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome.
    Lydic ML; McNurlan M; Bembo S; Mitchell L; Komaroff E; Gelato M
    Fertil Steril; 2006 Jul; 86(1):243-6. PubMed ID: 16730719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome.
    Lucidi RS; Thyer AC; Easton CA; Holden AE; Schenken RS; Brzyski RG
    Fertil Steril; 2005 Dec; 84(6):1755-7. PubMed ID: 16359984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study.
    Feiner JJ; McNurlan MA; Ferris RE; Mynarcik DC; Gelato MC
    Diabetes Obes Metab; 2008 Feb; 10(2):151-8. PubMed ID: 18190429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats.
    Cefalu WT; Wang ZQ; Zhang XH; Baldor LC; Russell JC
    J Nutr; 2002 Jun; 132(6):1107-14. PubMed ID: 12042418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial.
    Ashoush S; Abou-Gamrah A; Bayoumy H; Othman N
    J Obstet Gynaecol Res; 2016 Mar; 42(3):279-85. PubMed ID: 26663540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
    Romualdi D; Costantini B; Campagna G; Lanzone A; Guido M
    Fertil Steril; 2008 Nov; 90(5):1826-33. PubMed ID: 18166189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
    Narsing Rao L; Jacob JJ; Paul TV; Rajarathinam S; Thomas N; Seshadri MS
    J Pediatr Adolesc Gynecol; 2009 Apr; 22(2):91-5. PubMed ID: 19345914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of organic nucleic acids and serum biochemistry parameters by dietary chromium picolinate supplementation in swine model.
    Jiajun Y; Aiyun H; Shanshan Z; Minhong Z
    J Trace Elem Med Biol; 2011 Apr; 25(2):91-6. PubMed ID: 21511451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral chromium picolinate and control of glycemia in insulin-treated diabetic dogs.
    Schachter S; Nelson RW; Kirk CA
    J Vet Intern Med; 2001; 15(4):379-84. PubMed ID: 11467597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic characteristics according to insulin sensitivity in non-obese Korean women with polycystic ovary syndrome.
    Park HR; Choi Y; Lee HJ; Oh JY; Hong YS; Sung YA
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S233-7. PubMed ID: 17606307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and polycystic ovary syndrome.
    Lebinger TG
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):132-40. PubMed ID: 17940431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
    Højlund K; Glintborg D; Andersen NR; Birk JB; Treebak JT; Frøsig C; Beck-Nielsen H; Wojtaszewski JF
    Diabetes; 2008 Feb; 57(2):357-66. PubMed ID: 17977950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
    Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF
    Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suspected chromium picolinate-induced rhabdomyolysis.
    Martin WR; Fuller RE
    Pharmacotherapy; 1998; 18(4):860-2. PubMed ID: 9692662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
    Glintborg D; Højlund K; Andersen M; Henriksen JE; Beck-Nielsen H; Handberg A
    Diabetes Care; 2008 Feb; 31(2):328-34. PubMed ID: 18000176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.